The Lecanemab Clarity AD Open‐Label Extension in Early Alzheimer’s Disease: Initial Findings From the 48‐Month Analysis
In Clarity AD, the observed increasing treatment difference with ongoing lecanemab treatment in participants treated through 48 months versus ADNI matched placebo data is consistent with a durable disease-modifying effect. The long-term safety profile of lecanemab was confirmed, with no new safety signals.
Authors
- Michio Kanekiyo
- Shobha Dhadda (ORCID: https://orcid.org/0000-0002-7290-7168)
- Steven M. Hersch (ORCID: https://orcid.org/0000-0001-5948-6672)
- D. Li
- Michelle Gee
- Lynn D. Kramer
- Michael C. Irizarry
- Christopher H van Dyck
Institutions
- Yale University (US)
- Eisai (United Kingdom) (GB)
- Eisai (United States) (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70861_108905
- Citations
- 1
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.16